KRTX Stock Recent News

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials evaluating KarXT in schizophrenia will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held from May 30, 2023 to June 2, 2023 in Miami, Florid.

Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Director of Investor Relations Bill Meury - President and Chief Executive Officer Troy Ignelzi - Chief Financial Officer Andrew Miller - Founder and Chief Operating Officer Conference Call Participants Paul Matteis - Stifel Nick Lenard - JPMorgan Jason Gerberry - BofA Securities Neena Bitritto-Garg - Citi Laura Chico - Wedbush Securities Jay Olson - Oppenheimer David Amsellem - Piper Sandler Yatin Suneja - Guggenheim Securities Myles Minter - William Blair Jason Butler - JMP Securities Joseph Spak - RBC Capital Markets Rudy Li - SVB Securities Operator Welcome to the Karuna Therapeutics First Quarter 2023 Financial Results Conference Call. All participants are in a listen-only mode.

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the following upcoming investor conferences: BofA Securities 2023 Health Care Conference Date: Wednesday, May 10, 2023 Time: 5:00 p.m. PT (8:00 p.m. ET) 2023 RBC Capital Markets Global Healthcare Conference Date: Wednesday,.

89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a live conference call and webcast on Thursday, May 4, 2023 at 8:00 a.m. ET to review first quarter 2023 financial results and provide a general business update.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 8:00 a.m. ET. A live webcast of the presentation will be available on the Investor Relations page of Karuna's website at investors.karunatx.com.

Karuna Therapeutics focuses on therapies to treat neurological conditions. The stock is up more than 52% over the past year.

Data from a late-stage study shows that treatment with Karuna's (KRTX) lead candidate, KarXT, led to an early and sustained statistically significant reduction of symptoms of schizophrenia.

The stock price of Karuna Therapeutics Inc (NASDAQ: KRTX) fell by 3.56% after hours in the most recent trading session. This is why.